ClinicalTrials.gg
Active, not recruitingNCT03396172Updated Nov 4, 2026

FreeDom: Innovative Strategy for the Management of COPD Exacerbations

An interventional study of Control and FreeDom in Oxygen Deficiency and COPD Exacerbation, sponsored by Laval University. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Laval University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Hypoxia with a site in Canada — 7 open to participants now, 12 under way, 1 of them phase 3. Hypoxia · Canada.

Planned enrollment
7th of 41
100 · median 25
Started
2018
with 5 others
No phase
30 of 50
3 open now
Primary completion
2030-06
later than 11 of 11 live
Registered
30th of 50
by date
Lead sponsor
9 of 50
Laval University

Among the 50 studies in Hypoxia with a site in Canada, this one is the 7th largest by planned enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2018, is one of 30 with no phase, reaches primary completion later than 11 of the 11 other live ones, and was the 30th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

7 of the 50 studies in Hypoxia with a site in Canada are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Hypoxia with a site in Canada, or all of them as a file.
02

Study summary

The main objective of the study is to assess the "FreeDom" innovative strategy (FreeO2 at Domicile) to reduce hospitalization duration in patients with COPD exacerbation. This strategy associates early hospital discharge, automated O2 flow weaning with FreeO2 system, telemedicine and tele-rehabilitation.

The main hypothesis of this study is that the FreeDom strategy will reduce the number of hospitalization day by 50 percent at day 30.

Read the detailed description

The main objective of the study is to assess the "FreeDom" innovative strategy (FreeO2 at Domicile) to reduce hospitalization duration in patients with COPD exacerbation. This strategy will enable an early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation.

The main hypothesis of this study is that a strategy for an early return home with a home hospitalization managed by telemedicine will reduce the length of hospitalization by 50 percent from 30 days.

03

Conditions studied

  • Oxygen Deficiency
  • COPD Exacerbation

Keywords

  • COPD
  • Homecare
  • Oxygen
  • Telemedicine
  • Automated oxygen adjustment
  • Rehabilitation program
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All patients hospitalized for exacerbation for less than 48 hours will be considered.

  • known or suspected COPD to entry
  • Age > or = 40 years
  • Ex-smoker history (10 pack / year or more)
  • Acute Exacerbation: dyspnea of recent onset (less than 15 days)
  • The need for oxygen therapy with a moderate rate: \<6L / min to maintain SpO2 > 90% (for oxygen dependent patient, the oxygen flow must be higher than flow at home)

Exclusion criteria

Exclusion Criteria:

  • Refusal to consent to participate in the study,
  • Indication for an imminent intubation according to the pulmonologist,
  • Sleep Apnea
  • NIV used at home
  • Lack of FreeO2 system available at the time of randomization
  • Non-autonomous and alone at home
  • Patient alone at home
  • Patients who live more than 50 km from the hospital
  • Patient already included in the study within 3 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Control

    The intervention is an hospitalization with usual care. The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria

    Other: Control

  • Active comparator
    FreeDom

    FreeDom strategy (early discharge, automated weaning at home, telemedicine, telereadaptation): -initial conventional hospitalization before discharge home, O2 flow rate automatically titrated by FreeO2 (based on a SpO2 target). The hospital discharge will be possible if the definite criteria are met. After hospital discharge, patient will have home hospitalisation. Automated oxygen flow titration, patient education will be conducted for using the telemedicine system, for questionnaires and for the tele-rehabilitation program will be initiated for home hospitalization,

    Device: FreeDom

Interventions

  • OtherControl

    The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria

    Also known as: Usual oxygen administration and usual hospitalization

  • DeviceFreeDom

    Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation

    Also known as: Early Hospital discharge with home hospitalisation

06

What researchers measure

Primary outcomes

  1. The number of hospital days during COPD exacerbation at day 30.

    The objective of the study is to reduced the hospitalisation days by 50 % at day 30 during COPD exacerbation

    Time frame: 30 days

Secondary outcomes

  1. Rate of Emergency consultation and hospital readmission

    Rate of Emergency consultation and hospital readmission

    Time frame: 1 and 3 months

  2. Health Related Quality of Life

    Survey of health related quality of life

    Time frame: 1 and 3 months

  3. Cost of care at 3 months

    Economic evaluation about these 2 different strategy of COPD exacerbation management using micro-costing approach and including the cost of the FreeO2 technology

    Time frame: 3 months

  4. Oxygenation data (% of time in the SpO2 target, % of time with hypoxemia, % of time with hyperoxia)

    The continuous measurement of SpO2 and O2 flow rate with the FreeO2 device (only in the FreeDom strategy) will allow the calculation of the % of time within the SpO2 target (recorded in the FreeO2) ± 2%, with hypoxemia (% of time with SpO2 \< 85%) and with hyperoxia (% of time above SpO2 target +5%)

    Time frame: From inclusion to hospital discharge and from hospital discharge to the end of oxygen therapy (around one week after discharge)

  5. Number of consultations

    Number of consultation : phone call, video consultation, rehabilitation, home visit

    Time frame: 3 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for Jun 2030, 145 months after the start.

Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 145 months is above that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jun 2025 → Jun 2030 and completion Dec 2025 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2017
First posted
Jan 10, 2018
StartActual
May 24, 2018
Primary completionEst.
Jun 2030was Jun 2025
CompletionEst.
Dec 2030was Dec 2025
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 4, 2026
Sites
1 site added, 1 site removed
Show site
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec · Québec, Canada
Show 1 removed
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec · Quebec, Canada
Nov 4, 2026
Primary completion
Jun 2025→Jun 2030
Nov 4, 2026
Study completion
Dec 2025→Dec 2030
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Institut Universitaire de Cardiologie et de Pneumologie de Québec · Québec, Canada
    Show 1 removed
    • Institut Universitaire de Cardiologie et de Pneumologie de Québec · Quebec, Canada
    Primary completion Jun 2025→Jun 2030
    Study completion Dec 2025→Dec 2030
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03396172
Lead sponsor
Laval University
Responsible party
François Lellouche (Principal Investigator, Laval University) — Principal investigator
First posted
Jan 10, 2018
Start date
May 24, 2018
Primary completion
Jun 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

François Lellouche
principal investigator · Laval University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion